Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

CS 12192

Next Previous
X
Search
Drug Profile

CS 12192

Alternative Names: CS-12192

Latest Information Update: 28 Feb 2025

Price :

$50 *

Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Chipscreen Biosciences
  • Class Acrylamides; Amides; Amines; Anti-inflammatories; Antirheumatics; Benzamides; Fluorobenzenes; Nitriles; Propylamines; Pyrimidines; Skin disorder therapies; Small molecules
  • Mechanism of Action Janus kinase 1 inhibitors; Janus kinase 3 inhibitors; TBK1 protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Graft-versus-host disease
  • Preclinical Alopecia areata; Dermatitis; Inflammatory bowel diseases; Multiple sclerosis; Prurigo nodularis; Systemic lupus erythematosus
  • No development reported Rheumatoid arthritis

Most Recent Events

  • 28 Feb 2025 No recent reports of development identified for phase-I development in Rheumatoid-arthritis in China (PO)
  • 01 Feb 2024 Chipscreen Biosciences completes a phase I trial for Healthy volunteers in China (PO, Capsule) (NCT05922709)
  • 02 Jan 2024 Phase-I clinical trials in Graft-versus-host disease in USA (unspecified route) (Chipscreen Biosciences pipeline, January 2024)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top